Pulmonary infections therapeutic - Revagenix
Latest Information Update: 08 Mar 2024
At a glance
- Originator Revagenix
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Lung disorders
Most Recent Events
- 28 Feb 2024 Research programme: pulmonary infections therapeutic - is available for licensing as of 28 Feb 2024. https://www.revagenix.com/contact (Revagenix pipeline, February 2024)
- 28 Feb 2024 Preclinical trials in Lung disorders in USA (unspecified route) prior to February 2024 (Revagenix pipeline, February 2024)